Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 6, 2006, Pages 1223-1225

  Hayes, Vanessa M ^a,b,f   Severi, Gianluca ^c   Southey, Melissa C ^d,e   Padilla, Emma J D ^a   English, Dallas R ^c   Hopper, John L ^d   Giles, Graham G ^c   Sutherland, Robert L ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; MACROPHAGE INHIBITORY CYTOKINE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AUSTRALIA; CASE-CONTROL STUDIES; CYTOKINES; DNA, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 33745737943     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0063     Document Type: Article

References (15)

1. Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang H-P, Breit SN. MIC-1 is a novel TGF-β superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999;65:2-5.
2. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci U S A 1997;94:11514-9.
3. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-92.
4. Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61:6996-7001.
5. Nakamura T, Scorilas A, Stephan C, et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 2003;88:1101-4.
6. Rasiah KK, Kench JG, Gardiner-Garden M, et al. Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev 2006;15:711-6.
7. Hsieh CL, Oakley-Girvan I, Balise RR, et al. A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet 2001;69:148-58.
8. Wiklund F, Gillanders E, Bergh A, et al. Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 2003;57:290-7.
9. Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12:89-96.
10. Fairlie WD, Russell PK, Wu WM, et al. Epitope mapping of the transforming growth factor-β superfamily protein, macrophage inhibitory ccytokine-1 (MIC-1): identification of at least five distinct epitope specificities. Biochemistry 2001;40:65-73.
11. Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004;96:1248-54.
12. Seven G, Giles GG, Southey MC, et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst 2003;95:818-24.
13. Sham P. Statistics in human genetics. London: Arnold; 1998.
14. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1. The analysis of case-control studies. Vol. 32. Lyon: IARC; 1980.
15. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000.